Avalyn Pharma raised $300 million in an upsized IPO to fund late-stage development of reformulated inhaled respiratory therapies. The company priced its offering at $18 per share, with gross proceeds targeted to support Phase IIb and follow-on timelines for inhaled pirfenidone-based and nintedanib-based programs in progressive and idiopathic pulmonary fibrosis.